ArticleDigestive diseases and sciences2013
Efficacy of a metallic stent covered with a paclitaxel-incorporated membrane versus a covered metal stent for malignant biliary obstruction: a prospective comparative study.
Article in Digestive diseases and sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Efficacy of a Multiplex Paclitaxel Emission Stent Using a PluronicGut and liver · 2017Trial
- Article
- Advances in functional coatings on biliary stents.Regenerative biomaterials · 2024Review
- A review on biodegradable biliary stents: materials and future trends.Bioactive materials · 2022Review
- Indian College of Radiology and Imaging Evidence-Based Guidelines for Percutaneous Image-Guided Biliary Procedures.The Indian journal of radiology & imaging · 2021Review
- Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma.World journal of gastroenterology · 2020Article
- Influence of Polymer Composition on the Controlled Release of Docetaxel: A Comparison of Non-Degradable Polymer Films for Oesophageal Drug-Eluting Stents.Pharmaceutics · 2020Article
- Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation.International journal of molecular sciences · 2020Article
- Endoscopic Palliation for Biliary and Pancreatic Malignancies: Recent Advances.Clinical endoscopy · 2019Article
- Safety Evaluation of Paclitaxel-Eluting Biliary Metal Stent with Sodium Caprate in Porcine Biliary Tract.Gut and liver · 2019Article
- Endoscopic retrograde cholangiopancreatography, lights and shadows: Handle with care.World journal of gastrointestinal endoscopy · 2019Review
- Piperlongumine-Eluting Gastrointestinal Stent Using Reactive Oxygen Species-Sensitive Nanofiber Mats for Inhibition of Cholangiocarcinoma Cells.Nanoscale research letters · 2019Article
- Palliative Percutaneous Biliary Interventions in Malignant High Bile Duct Obstruction.Seminars in interventional radiology · 2017Review
- Partially Covered Metal Stents May Not Prolong Stent Patency Compared to Uncovered Stents in Unresectable Malignant Distal Biliary Obstruction.Gut and liver · 2017Article
- Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for inhibition of cholangiocarcinoma cells.International journal of nanomedicine · 2017Article
- A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.Biomaterials · 2016Article
- Malignant biliary obstruction: From palliation to treatment.World journal of gastrointestinal oncology · 2016Review
- Basic Knowledge about Metal Stent Development.Clinical endoscopy · 2016Review
- Drug eluting biliary stents to decrease stent failure rates: A review of the literature.World journal of gastrointestinal endoscopy · 2016Review
- Cholangiocarcinoma and malignant bile duct obstruction: A review of last decades advances in therapeutic endoscopy.World journal of gastrointestinal endoscopy · 2015Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe placement of a self-expandable metallic stent (SEMS) is a widely used nonsurgical treatment method in patients with unresectable malignant biliary obstructions but SEMS is susceptible to occlusion by tumor ingrowth or overgrowth.
aimThe efficacy and safety of a metallic stent covered with a paclitaxel-incorporated membrane (MSCPM) in which paclitaxel provided an antitumoral effect was compared prospectively with those of a covered metal stent (CMS) in patients with malignant biliary obstructions.
methodsPatients with unresectable distal malignant biliary obstructions (n = 106) were prospectively enrolled in this study at multiple treatment centers. A MSCPM was inserted endoscopically in 60 patients, and a CMS was inserted in 46 patients. Patients underwent systemic chemotherapy regimens alternatively according to disease characteristics.
resultsThe two groups did not differ significantly in mean age, male to female ratio, or mean follow-up period. Stent occlusion due to tumor ingrowth occurred in 12 patients who received MSCPMs and in eight patients who received CMSs. Stent patency and survival time did not differ significantly between the two groups (p = 0.116, 0.981). Chemotherapy had no influence on stent patency, but gemcitabine-based chemotherapy was a significant prognostic factor for survival time (p = 0.012). Complications, including cholangitis and pancreatitis, were found to be acceptable in both groups.
conclusionsAlthough the use of a MSCPM produced no significant differences in stent patency or patient survival in patients with malignant biliary obstructions compared with the use of a CMS, this study demonstrated that MSCPM can be used safely in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.